Related references
Note: Only part of the references are listed.Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases
Jonathan Kay et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab
Primal Kaur et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Sirukumab: a promising therapy for rheumatoid arthritis
Eleftherios Pelechas et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2017)
Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study
Stanley Cohen et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Jasvinder A. Singh et al.
ARTHRITIS CARE & RESEARCH (2016)
The changing landscape of biosimilars in rheumatology
Thomas Doerner et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab
Jyoti Velayudhan et al.
BIODRUGS (2016)
Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab
Jennifer Liu et al.
BIODRUGS (2016)
A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective
Peter C. Taylor et al.
RHEUMATOLOGY INTERNATIONAL (2016)
A Randomized Comparative Effectiveness Study of Oral Triple Therapy Versus Etanercept Plus Methotrexate in Early Aggressive Rheumatoid Arthritis The Treatment of Early Aggressive Rheumatoid Arthritis Trial
Larry W. Moreland et al.
ARTHRITIS AND RHEUMATISM (2012)
Adalimumab in the treatment of rheumatoid arthritis
Paraskevi V. Voulgari et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2012)
Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
Daniel Tracey et al.
PHARMACOLOGY & THERAPEUTICS (2008)
Estimates of the prevalence of arthritis and other rheumatic conditions in the United States
Charles G. Helmick et al.
ARTHRITIS AND RHEUMATISM (2008)
Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution
Annabel Kuek et al.
POSTGRADUATE MEDICAL JOURNAL (2007)
Adalimumab for rheumatoid arthritis
Paraskevi V. Voulgari et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2006)
Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: A systematic review
Yannis Alamanos et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2006)
The burden of musculoskeletal disease - a global perspective
Peter M. Brooks
CLINICAL RHEUMATOLOGY (2006)
Epidemiology of adult rheumatoid arthritis
Y Alamanos et al.
AUTOIMMUNITY REVIEWS (2005)
Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy - A randomized, placebo-controlled, 52-week trial
EC Keystone et al.
ARTHRITIS AND RHEUMATISM (2004)
Adalimumab - A review of its use in rheumatoid arthritis
LM Bang et al.
BIODRUGS (2004)
Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed
BA van de Putte et al.
ANNALS OF THE RHEUMATIC DISEASES (2004)
Adalimumab, a fully human anti-tumor necrosis factor a monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate - The ARMADA trial
ME Weinblatt et al.
ARTHRITIS AND RHEUMATISM (2003)
Share Paper
